Combined, these data establish that LSP1 is a heritable iTME modifier that correlates with BrCa patient survival and closely resembles the characteristics of known I-O targets, which collectively suggest that LSP1 is a potential I-O therapeutic target with high translational potential. This evidence concerns the gene LSP1 and invasive breast carcinoma.